---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-036129"
form_type: "8-K"
ticker: "SCNI"
cik: "0001611747"
company_name: "Scinai Immunotherapeutics Ltd."
filed_at: "2023-05-04T23:59:59+00:00"
generated_at: "2026-06-15T22:05:37.545989+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "low"
source: SEC EDGAR
---

# BiondVax publishes investor presentation on May 4, 2023; no financial results disclosed

## Summary
- Presentation made available on company website and discussed in meetings starting May 4, 2023.
- Forward-looking statements reference NanoAbs pipeline, manufacturing facility, and potential collaborations.
- No new financial guidance, earnings, or material operational updates were provided in the filing.

## SEC filing metadata
- accession: 0001213900-23-036129
- form_type: 8-K
- ticker: SCNI
- cik: 0001611747
- company_name: Scinai Immunotherapeutics Ltd.
- filed_at: 2023-05-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1611747/000121390023036129/0001213900-23-036129-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1611747/000121390023036129/ea177973-8k_biondvax.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-036129
- JSON: https://secwatch.observer/filing/0001213900-23-036129.json
- Plain text: https://secwatch.observer/filing/0001213900-23-036129.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.